Abstract:Alzheimer’s disease (AD) pathogenesis is widely believed to be associated with the production and deposition of the β-amyloid peptide (Aβ) and neurofibrillary tangles (NFTs) which are composed of a highly-phosphorylated form of the microtubule-associated protein tau. Based on the above hypothesis, there are currently no sufficiently effective technologies and drugs for early detection and treatment of AD. Even the most promising new drug Lecanemab that is based on an anti-amyloid monoclonal antibody therapy, has only partially slowed down the cognitive performance of patients with mild impairment caused by Alzheimer's disease. The main symptoms of AD brain tissue lesions in patients are the deposition of β-amyloid peptide and the hyperphosphorylation of tau protein, which aggregates the microtubule structure of neurons. Therefore, Aβ deposition and hyperphosphorylation of Tau are important pathological biomarkers of Alzheimer's disease. Therefore, the main targets of research for AD prevention, detection and pharmaceuticals are still Aβ and Tau protein. The aim of this study was to detect the changes of Aβ and Tau proteins in the mouse brain tissue with AD and control samples using Visible Resonance Raman (VRR) spectroscopic technology. An attempt was made to develop criteria for the detection of early AD lesions by optical spectroscopy technology. The VRR spectra of AD, the control mouse brain tissues, and Aβ and Tau proteins were recorded and analyzed. The AD and the control mouse brain tissue samples were selected from the thalamus, frontal lobe cortex and hippocampus brain areas. VRR technology with high spatial resolution and the resonance-enhanced features of certain protein molecules is first used in this study to detect and characterize the changes of Aβ and Tau proteins in AD mouse brain model. The optical spectroscopy biomarkers of AD and Control brain tissue were identified in fingerprint and the high-wavenumber regions. The Raman spectra of the secondary structure of protein in amide (I-II-III-B-A) are detected and analyzed. The results indicate that the intensity of Amide I decreased at the 1666 cm-1 corresponding to the β-sheet structure, and the intensity of the amide III bands (1220- 1320 cm-1) increased in all AD brain tissues. It was also observed that the Raman peaks of 1448 and 980 cm-1 related to the abundance of proline, serine, and threonine at tau phosphorylation sites were significantly enhanced in the frontal lobe cortex and hippocampus of AD brain tissues. The intensity ratio biomarker of high phosphorylation in the high wavenumber range from 2898 to 2932 cm-1 increased in all AD brain tissues. Changes of protein secondary conformation and abnormally phosphorylated tau or tauopathies were observed. In summary, VRR is a sensitive tool for characterizing protein structural changes and monitoring the tau phosphorylation. It may potentially be used for early detection of AD.

Distinguishing Amyloid Β-Protein in a Mouse Model of Alzheimer’s Disease by Label-Free Vibrational Imaging

Label-free imaging of amyloid plaques in Alzheimer's disease with stimulated Raman scattering microscopy.

Quantitative chemical imaging of amyloid-β plaques with Raman micro-spectroscopy in human Alzheimer's diseased brains

Amyloid Beta and Tau Protein Metabolic Changes Detected by Visible Resonance Raman Scattering Microscopy in Alzheimer's Disease Mouse Model

A Novel Viscosity Sensitive Hemicyanine Fluorescent Dye for Real-Time Imaging of Amyloid-Β Aggregation

Label free visualization of amyloid plaques in Alzheimer's disease with polarization-sensitive photoacoustic Mueller matrix tomography

Long-Term Repeatable In Vivo Monitoring of Amyloid-β Plaques and Vessels in Alzheimer's Disease Mouse Model with Combined TPEF/CARS Microscopy

Unlocking the Molecular Variations of a Micron-Scale Amyloid Plaque in an Early Stage Alzheimer’s Disease by a Cellular-Resolution Mass Spectrometry Imaging Platform

Multiscale optical and optoacoustic imaging of amyloid-β deposits in mice

Visualizing Aβ Deposits in Live Young AD Model Mice with a Simple Red/near-Infrared-fluorescent AIEgen

Synthesis and evaluation of curcumin-based near-infrared fluorescent probes for detection of amyloid β peptide in Alzheimer mouse models

Multimodal microscopy for characterization of amyloid-${\unicode[Times]{x3B2}}$ plaques biomarkers in animal model of Alzheimer's disease

Mapping cellular stress and lipid dysregulation in Alzheimer-related progressive neurodegeneration using label-free Raman microscopy

Highly Sensitive Near-Infrared Fluorophores for in Vivo Detection of Amyloid-β Plaques in Alzheimer’s Disease

High-fidelity imaging of amyloid-beta deposits with an ultrasensitive fluorescent probe facilitates the early diagnosis and treatment of Alzheimer's Disease

Noninvasive Visualization of Amyloid-Beta Deposits in Alzheimer's Amyloidosis Mice via Fluorescence Molecular Tomography Using Contrast Agent

Environment-Sensitive Near-Infrared Probe for Fluorescent Discrimination of Aβ and Tau Fibrils in AD Brain.

Amyloid-β Deposits Target Efficient Near-Infrared Fluorescent Probes: Synthesis, in Vitro Evaluation and in Vivo Imaging.

Tailoring near-infrared amyloid-β probes with high-affinity and low background based on CN and amphipathic regulatory strategies and in vivo imaging of AD mice

Label-free autofluorescence and hyperspectral imaging of cerebral amyloid-β lesions in aged squirrel monkeys

Rational design synthesis and evaluation of a novel near-infrared fluorescent probe for selective imaging of amyloid-β aggregates in Alzheimer's disease